[{"id":"424f1715-a08a-4e86-a255-1bc30e3c69e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03203525","created_at":"2021-01-18T15:47:47.088Z","updated_at":"2025-02-25T15:42:56.837Z","phase":"Phase 1","brief_title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","source_id_and_acronym":"NCT03203525","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • temsirolimus • pegylated liposomal doxorubicin • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/23/2020","start_date":" 06/23/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-10"},{"id":"b5993f06-cb2c-4080-9676-30541427ea90","acronym":"","url":"https://clinicaltrials.gov/study/NCT00980460","created_at":"2021-01-18T03:49:34.064Z","updated_at":"2025-02-25T16:50:58.740Z","phase":"Phase 3","brief_title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","source_id_and_acronym":"NCT00980460","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • doxorubicin hydrochloride • irinotecan • temsirolimus • vincristine • fluorouracil topical • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 236","initiation":"Initiation: 09/14/2009","start_date":" 09/14/2009","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2025-02-04"},{"id":"d16edb9e-05b0-4a67-8757-e2748c115c02","acronym":"ARST1431","url":"https://clinicaltrials.gov/study/NCT02567435","created_at":"2024-01-09T20:20:40.495Z","updated_at":"2025-02-25T16:51:34.054Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","source_id_and_acronym":"NCT02567435 - ARST1431","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FOXO1 • PAX3 • PAX7","pipe":"","alterations":" ","tags":["FOXO1 • PAX3 • PAX7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • irinotecan • temsirolimus • vincristine • vinorelbine tartrate • dactinomycin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 325","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 10/16/2025","study_completion_date":" 10/16/2025","last_update_posted":"2025-02-04"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"613dfa54-e318-471f-a8ed-a12b2572968b","acronym":"CAPTUR","url":"https://clinicaltrials.gov/study/NCT03297606","created_at":"2021-01-18T16:17:30.914Z","updated_at":"2025-02-25T13:52:23.697Z","phase":"Phase 2","brief_title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","source_id_and_acronym":"NCT03297606 - CAPTUR","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • sunitinib • Perjeta (pertuzumab) • Cotellic (cobimetinib) • bosutinib • Tukysa (tucatinib) • temsirolimus • axitinib • Erivedge (vismodegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-11-12"},{"id":"0300bd11-3c88-4727-a08a-0abd664e0d55","acronym":"","url":"https://clinicaltrials.gov/study/NCT05773326","created_at":"2023-03-17T14:02:34.285Z","updated_at":"2024-07-02T16:35:02.449Z","phase":"Phase 1","brief_title":"Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG","source_id_and_acronym":"NCT05773326","lead_sponsor":"Nader Sanai","biomarkers":" PIK3CA • PTEN • mTOR • PIK3R1 • PIK3C2B","pipe":" | ","alterations":" PIK3CA mutation • MTOR mutation • PIK3CA mutation + PTEN mutation • PIK3R1 mutation","tags":["PIK3CA • PTEN • mTOR • PIK3R1 • PIK3C2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • MTOR mutation • PIK3CA mutation + PTEN mutation • PIK3R1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/15/2023","start_date":" 05/15/2023","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2024-05-21"},{"id":"8c77c515-8fd7-47a1-b2a0-d210db442390","acronym":"","url":"https://clinicaltrials.gov/study/NCT00977574","created_at":"2021-01-18T03:48:50.533Z","updated_at":"2024-07-02T16:35:03.140Z","phase":"Phase 2","brief_title":"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT00977574","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT1","pipe":"","alterations":" ","tags":["AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • temsirolimus • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Ixempra (ixabepilone) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • patupilone (EPO 906)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 349","initiation":"Initiation: 09/14/2009","start_date":" 09/14/2009","primary_txt":" Primary completion: 01/31/2015","primary_completion_date":" 01/31/2015","study_txt":" Completion: 03/06/2025","study_completion_date":" 03/06/2025","last_update_posted":"2024-05-17"},{"id":"afe413d7-7e85-457e-9af3-9c556a34d9ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT01396408","created_at":"2021-01-18T05:44:09.814Z","updated_at":"2024-07-02T16:35:17.762Z","phase":"Phase 2","brief_title":"A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT01396408","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PTEN • STK11 • NF1","pipe":" | ","alterations":" EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification","tags":["PTEN • STK11 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • temsirolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 02/09/2012","start_date":" 02/09/2012","primary_txt":" Primary completion: 07/06/2015","primary_completion_date":" 07/06/2015","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-26"},{"id":"a8b6f6a9-6202-45d1-8f50-d1a889349779","acronym":"NOA-20","url":"https://clinicaltrials.gov/study/NCT03158389","created_at":"2021-01-18T15:34:18.016Z","updated_at":"2024-07-02T16:35:35.452Z","phase":"Phase 1/2","brief_title":"NCT Neuro Master Match - N²M² (NOA-20)","source_id_and_acronym":"NCT03158389 - NOA-20","lead_sponsor":"University Hospital Heidelberg","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Ibrance (palbociclib) • Alecensa (alectinib) • temsirolimus • Erivedge (vismodegib) • idasanutlin (RG7388) • Apocept (asunercept)"],"overall_status":"Completed","enrollment":" Enrollment 228","initiation":"Initiation: 05/07/2018","start_date":" 05/07/2018","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 02/22/2023","study_completion_date":" 02/22/2023","last_update_posted":"2023-09-28"},{"id":"8e05a524-c610-45fc-9266-0aa9f0c967e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00593060","created_at":"2021-01-18T02:11:43.549Z","updated_at":"2024-07-02T16:35:47.293Z","phase":"Phase 1","brief_title":"Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer","source_id_and_acronym":"NCT00593060","lead_sponsor":"Jeffrey W. Clark, MD","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • temsirolimus"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 11/01/2007","start_date":" 11/01/2007","primary_txt":" Primary completion: 10/01/2009","primary_completion_date":" 10/01/2009","study_txt":" Completion: 11/01/2010","study_completion_date":" 11/01/2010","last_update_posted":"2023-05-24"},{"id":"07fc2b93-1554-4f3a-a0bb-4d6401986242","acronym":"ALLTARGETOBS","url":"https://clinicaltrials.gov/study/NCT05832125","created_at":"2023-04-27T14:04:52.886Z","updated_at":"2024-07-02T16:35:49.471Z","phase":"","brief_title":"Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05832125 - ALLTARGETOBS","lead_sponsor":"Versailles Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2023-04-27"},{"id":"9912c104-2619-4ba2-b95c-bb5c454672a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04650451","created_at":"2021-01-19T20:40:10.787Z","updated_at":"2024-07-02T16:35:49.989Z","phase":"Phase 1/2","brief_title":"Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors","source_id_and_acronym":"NCT04650451","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • BPX-603"],"overall_status":"Suspended","enrollment":" Enrollment 220","initiation":"Initiation: 12/07/2020","start_date":" 12/07/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 01/02/2027","study_completion_date":" 01/02/2027","last_update_posted":"2023-04-20"},{"id":"89fea682-b243-4d0a-b33b-68ffee2754d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05144698","created_at":"2021-12-03T17:53:38.066Z","updated_at":"2024-07-02T16:35:51.936Z","phase":"Phase 1/2","brief_title":"RAPA-201 Therapy of Solid Tumors","source_id_and_acronym":"NCT05144698","lead_sponsor":"Rapa Therapeutics LLC","biomarkers":" EGFR • ALK • BRCA","pipe":" | ","alterations":" EGFR mutation • ALK translocation • BRCA mutation","tags":["EGFR • ALK • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • temsirolimus • sirolimus • RAPA-201"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-03-30"},{"id":"77486169-ba74-4b64-9978-ff3c0551430b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01381692","created_at":"2021-01-18T05:39:57.012Z","updated_at":"2024-07-02T16:36:23.548Z","phase":"Phase 2","brief_title":"Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma","source_id_and_acronym":"NCT01381692","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • temsirolimus • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 07/20/2011","start_date":" 07/20/2011","primary_txt":" Primary completion: 12/08/2014","primary_completion_date":" 12/08/2014","study_txt":" Completion: 09/01/2021","study_completion_date":" 09/01/2021","last_update_posted":"2021-10-04"},{"id":"26dd9f11-390e-4ad9-a572-278f8a7b6546","acronym":"","url":"https://clinicaltrials.gov/study/NCT01687673","created_at":"2021-01-18T07:19:14.901Z","updated_at":"2024-07-02T16:36:37.772Z","phase":"Phase 2","brief_title":"Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT01687673","lead_sponsor":"University of California, San Francisco","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • temsirolimus"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 10/05/2012","start_date":" 10/05/2012","primary_txt":" Primary completion: 04/26/2016","primary_completion_date":" 04/26/2016","study_txt":" Completion: 01/09/2020","study_completion_date":" 01/09/2020","last_update_posted":"2020-12-07"},{"id":"abb6e927-0be3-4563-adee-1a376581cd86","acronym":"POEM","url":"https://clinicaltrials.gov/study/NCT02093598","created_at":"2021-01-18T09:39:41.565Z","updated_at":"2024-07-02T16:36:38.120Z","phase":"Phase 2a","brief_title":"POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus","source_id_and_acronym":"NCT02093598 - POEM","lead_sponsor":"MedSIR","biomarkers":" MYC • PTEN • EIF4EBP1","pipe":"","alterations":" ","tags":["MYC • PTEN • EIF4EBP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 05/01/2012","start_date":" 05/01/2012","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2020-11-27"},{"id":"3a37952b-693b-4428-a2f1-7aed93437baa","acronym":"","url":"https://clinicaltrials.gov/study/NCT00376688","created_at":"2021-01-18T01:18:27.841Z","updated_at":"2024-07-02T16:36:49.680Z","phase":"Phase 2","brief_title":"Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT00376688","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 07/11/2006","start_date":" 07/11/2006","primary_txt":" Primary completion: 06/12/2008","primary_completion_date":" 06/12/2008","study_txt":" Completion: 12/16/2019","study_completion_date":" 12/16/2019","last_update_posted":"2020-02-24"},{"id":"7209ebe1-7911-4cd0-b281-ce03cba0b938","acronym":"","url":"https://clinicaltrials.gov/study/NCT01196429","created_at":"2021-01-18T04:47:25.740Z","updated_at":"2024-07-02T16:36:57.178Z","phase":"Phase 2","brief_title":"Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer","source_id_and_acronym":"NCT01196429","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • WT1","pipe":"","alterations":" ","tags":["ER • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • docetaxel • temsirolimus"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 01/01/2015","primary_completion_date":" 01/01/2015","study_txt":" Completion: 01/01/2015","study_completion_date":" 01/01/2015","last_update_posted":"2019-08-08"},{"id":"38f7e812-7b2f-4a13-9f7b-f337348cbfb4","acronym":"SARC023","url":"https://clinicaltrials.gov/study/NCT02008877","created_at":"2021-01-18T09:10:25.745Z","updated_at":"2024-07-02T16:36:59.593Z","phase":"Phase 1/2","brief_title":"SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)","source_id_and_acronym":"NCT02008877 - SARC023","lead_sponsor":"Sarcoma Alliance for Research through Collaboration","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • sirolimus • ganetespib (ADX-1612)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2019-05-15"},{"id":"c4e04cb1-622c-4892-9361-08df3d5244fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01010126","created_at":"2021-01-18T03:57:18.273Z","updated_at":"2024-07-02T16:37:03.490Z","phase":"Phase 2","brief_title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","source_id_and_acronym":"NCT01010126","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temsirolimus"],"overall_status":"Completed","enrollment":" Enrollment 252","initiation":"Initiation: 09/08/2009","start_date":" 09/08/2009","primary_txt":" Primary completion: 03/13/2017","primary_completion_date":" 03/13/2017","study_txt":" Completion: 03/13/2017","study_completion_date":" 03/13/2017","last_update_posted":"2019-01-25"},{"id":"1143e6ad-4fb3-4eac-a9d3-83858e654c43","acronym":"","url":"https://clinicaltrials.gov/study/NCT01614795","created_at":"2021-01-18T06:55:05.325Z","updated_at":"2024-07-02T16:37:04.745Z","phase":"Phase 2","brief_title":"Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma","source_id_and_acronym":"NCT01614795","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" mTOR • IR","pipe":"","alterations":" ","tags":["mTOR • IR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 06/18/2012","start_date":" 06/18/2012","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2018-12-11"},{"id":"8ac5c49a-ebdb-4486-b1c0-249e9c939e6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00378703","created_at":"2021-01-18T01:18:58.930Z","updated_at":"2024-07-02T16:37:05.337Z","phase":"Phase 2","brief_title":"Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer","source_id_and_acronym":"NCT00378703","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • sorafenib • temsirolimus"],"overall_status":"Completed","enrollment":" Enrollment 361","initiation":"Initiation: 09/14/2007","start_date":" 09/14/2007","primary_txt":" Primary completion: 02/07/2014","primary_completion_date":" 02/07/2014","study_txt":" Completion: 03/21/2017","study_completion_date":" 03/21/2017","last_update_posted":"2018-11-14"},{"id":"12bdc65c-dfc7-4a9a-bb78-fed395d1103a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01111825","created_at":"2021-01-18T04:24:16.145Z","updated_at":"2024-07-02T16:37:06.590Z","phase":"Phase 1/2","brief_title":"Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer","source_id_and_acronym":"NCT01111825","lead_sponsor":"Puma Biotechnology, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • temsirolimus"],"overall_status":"Completed","enrollment":" Enrollment 99","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 07/01/2016","study_completion_date":" 07/01/2016","last_update_posted":"2018-09-26"},{"id":"0d679223-9103-4be2-b751-1e53947446c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01025453","created_at":"2021-01-18T04:01:31.385Z","updated_at":"2024-07-02T16:37:07.873Z","phase":"Phase 2","brief_title":"Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer","source_id_and_acronym":"NCT01025453","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TG","pipe":" | ","alterations":" BRAF mutation","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • temsirolimus"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 12/01/2009","start_date":" 12/01/2009","primary_txt":" Primary completion: 01/16/2018","primary_completion_date":" 01/16/2018","study_txt":" Completion: 01/16/2018","study_completion_date":" 01/16/2018","last_update_posted":"2018-08-15"}]